Factors Influencing Survival in Children with Recurrent Neuroblastoma

Journal of Pediatric Hematology/Oncology

Volumn 26, Issue 4, 2004, Pages 227-232

  Lau, Loretta ^a   Tai, Derek ^a   Weitzman, Sheila ^a   Grant, Ronald ^a   Baruchel, Sylvain ^a   Malkin, David ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Neuroblastoma; Prognosis; Recurrence; Salvage therapy; Survival analysis

Indexed keywords

ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HUMAN; LONG TERM CARE; MALE; NEUROBLASTOMA; ONCOGENE C MYB; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; RETROSPECTIVE STUDY; SALVAGE THERAPY; STEM CELL TRANSPLANTATION;

CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; MALE; NEUROBLASTOMA; RECURRENCE; RETROSPECTIVE STUDIES; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 13144249459     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200404000-00003     Document Type: Article

References (18)

1. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med. 1999;341:1165-1173.
2. Fouladi M, Stempak D, Gammon J, et al. Phase I trial of a twice-daily regime of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma. Cancer. 2001;92:914-923.
3. Blaney S, Berg SL, Pratt C, et al. A phase I study of irinotecan in pediatric patients: a Pediatric Oncology Group study. Clin Cancer Res. 2001;7:32-37.
4. Castel V, Cañete C, Melero T, et al. Results of the Cooperative Protocol (N-III-95) for metastatic relapses and refractory neuroblastoma. Med Pediatr Oncol. 2000;35:724-726.
5. rd, Stine KC, Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group study. J Clin Oncol. 2001;19:3463-3469.
6. Ladenstein R, Lasset C, Hartmann O, et al. Impact of megatherapy on survival after relapse from stage 4 neuroblastoma in patients over 1 year of age at diagnosis: a report from the European Group for Bone Marrow Transplantation. J Clin Oncol. 1993;11:2330-2341.
7. Kushner BH, Kramer K, Cheung NV. Chronic neuroblastoma. Indolent stage 4 disease in children. Cancer. 2002;95:1366-1375.
8. Shimada H, Chatten J, Newton WA Jr, et al. Histopathologic prognostic factors in neuroblastic tumours: definition of subtypes of ganglioneuroblastoma and as age-linked classification of neuroblastomas. J Natl Cancer Inst. 1984;73:405-416.
9. Matthay KK, Atkinson JB, Stram DO, et al. Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: a Children's Cancer Group pilot study. J Clin Oncol. 1993;11:2226-2233.
10. George RE, Variend S, Cullinane C, et al. Relationship between histological features, MYCN amplification, and prognosis: A UKCCSG study. Med Pediatr Oncol. 2001;36:169-176.
11. Maris JM, Guo C, Blake D, et al. Comprehensive analysis of chromosome 1p deletion in neuroblastoma. Med Pediatr Oncol. 2001;36:32-36.
12. Tonini GP, Boni L, Pession A, et al. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: The Italian experience with 295 children. J Clin Oncol. 1997;15:85-93.
13. Campbell LA, Seeger RC, Harris RE, et al. Escalating dose of continuous infusion combination chemotherapy for refractory neuroblastoma. J Clin Oncol. 1993;11:623-629.
14. Alvarado CS, Kretschmar C, Joshi VV, et al. Chemotherapy for patients with recurrent or refractory neuroblastoma: a POG phase II study. J Pediatr Hematol Oncol. 1997;19:62-67.
15. Nitschke R, Parkhurst J, Sullivan J, et al. Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study. J Pediatr Hematol Oncol. 1998;20:315-318.
16. Yu A, Uttenreuther-Fischer M, Huang C-S, et al. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol. 1998;16:2169-2180.
17. Voûte PA, Van der Kleij A, De Kraker J, et al. Clinical experience with radiation enhancement by hyperbaric oxygen in children with recurrent neuroblastoma stage IV. Eur J Cancer. 1995;31A:596-600.
18. Cotterill SJ, Pearson ADJ, Pritchard J, et al. Late relapse and prognosis for neuroblastoma patients surviving 5 years or more: a report from the European Neuroblastoma Study Group survey. Med Pediatr Oncol. 2001;36:235-238.